Virbac reported a 7.7% revenue increase at constant exchange rates and scope in Q1 2026, reaching €384 million. Growth was balanced across companion animal (+9.9%) and farm animal (+8.4%) segments, with notable 15% growth in priority Supercharge platforms. North America led with a 20.7% rise, supported by the Thyronorm acquisition, while Europe and International regions also showed solid gains. Despite currency headwinds and some regional challenges, Virbac maintained its 2026 revenue growth guidance of 5.5% to 7.5% and expects adjusted operating income around 17%.
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
ASUS has introduced two new Chromebooks in the US market: the budget-friendly CM15 laptop and the versatile CM32 Detachable 2-in-1 device. Both run on the MediaTek Kompanio 540 processor, offer up to 12 hours of battery life, and feature military-gra...
Slate Medicines, a biotech firm focused on migraine treatments, has appointed Mark W. Hahn to its Board of Directors. Hahn brings over 25 years of experience in life sciences, including leading companies through financial milestones and FDA approvals...
Goldman Sachs reported robust Q2 FY2026 results, with net earnings growing at an annualized rate of 38%. The firm raised $31 billion in private credit and saw a 130% year-over-year surge in equity underwriting revenues, driven by major deals and IPO ...
The Bitwise Bitcoin ETF (BITB) features competitive fees and tight trading spreads comparable to industry leaders like IBIT and FBTC. Despite strong execution on cost and trading efficiency, BITB's market share and asset growth have stalled due to li...
